160 related articles for article (PubMed ID: 26631613)
1. Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.
Silva IP; Salhi A; Giles KM; Vogelsang M; Han SW; Ismaili N; Lui KP; Robinson EM; Wilson MA; Shapiro RL; Pavlick A; Zhong J; Kirchhoff T; Osman I
Clin Cancer Res; 2016 May; 22(10):2377-85. PubMed ID: 26631613
[TBL] [Abstract][Full Text] [Related]
2. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.
Glubb DM; Cerri E; Giese A; Zhang W; Mirza O; Thompson EE; Chen P; Das S; Jassem J; Rzyman W; Lingen MW; Salgia R; Hirsch FR; Dziadziuszko R; Ballmer-Hofer K; Innocenti F
Clin Cancer Res; 2011 Aug; 17(16):5257-67. PubMed ID: 21712447
[TBL] [Abstract][Full Text] [Related]
3. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero Á; Albarran MI; Baños N; Durán Y; Bonilla V; Sarno F; Camacho-Artacho M; Sanchez-Perez T; Perea S; Álvarez R; De Martino A; Lietha D; Blanco-Aparicio C; Cubillo A; Domínguez O; Martínez-Torrecuadrada JL; Hidalgo M
Clin Cancer Res; 2018 Aug; 24(15):3550-3559. PubMed ID: 29588308
[No Abstract] [Full Text] [Related]
4. Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes.
Ibrahim M; Illa-Bochaca I; Fa'ak F; Monson KR; Ferguson R; Lyu C; Vega-Saenz de Miera E; Johannet P; Chou M; Mastroianni J; Darvishian F; Kirchhoff T; Zhong J; Krogsgaard M; Osman I
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201446
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
[TBL] [Abstract][Full Text] [Related]
6. Association of polymorphisms/haplotypes of the genes encoding vascular endothelial growth factor and its KDR receptor with recurrent pregnancy loss.
Su MT; Lin SH; Lee IW; Chen YC; Kuo PL
Hum Reprod; 2011 Apr; 26(4):758-64. PubMed ID: 21257617
[TBL] [Abstract][Full Text] [Related]
7. The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas.
Zaman N; Dass SS; DU Parcq P; Macmahon S; Gallagher L; Thompson L; Khorashad JS; LimbÄck-Stanic C
Cancer Genomics Proteomics; 2020; 17(6):715-727. PubMed ID: 33099473
[TBL] [Abstract][Full Text] [Related]
8. Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer.
Marotta V; Sciammarella C; Capasso M; Testori A; Pivonello C; Chiofalo MG; Gambardella C; Grasso M; Antonino A; Annunziata A; Macchia PE; Pivonello R; Santini L; Botti G; Losito S; Pezzullo L; Colao A; Faggiano A
J Clin Endocrinol Metab; 2017 Feb; 102(2):661-671. PubMed ID: 27849428
[TBL] [Abstract][Full Text] [Related]
9. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
Kim DS; Franklyn JA; Boelaert K; Eggo MC; Watkinson JC; McCabe CJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4603-11. PubMed ID: 16926250
[TBL] [Abstract][Full Text] [Related]
10. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor KDR].
Chen XL; Liu LC; Xu ZG; Li Z; Li RW; Gao RJ; Wang S; Zhang M; Guo H
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):578-82. PubMed ID: 19102933
[TBL] [Abstract][Full Text] [Related]
12. A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells.
Kunze K; Spieker T; Gamerdinger U; Nau K; Berger J; Dreyer T; Sindermann JR; Hoffmeier A; Gattenlöhner S; Bräuninger A
Cancer Res; 2014 Nov; 74(21):6173-83. PubMed ID: 25252913
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of angiogenesis with expression of vascular endothelial growth factor and its receptors in lung carcinoma].
Zhang G; Zhao M; Xu M; Yang Y; Wang M; Yang C
Zhonghua Jie He He Hu Xi Za Zhi; 2002 Feb; 25(2):89-93. PubMed ID: 11953105
[TBL] [Abstract][Full Text] [Related]
14. Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans.
Jang MJ; Jeon YJ; Kim JW; Cho YK; Lee SK; Hwang SG; Oh D; Kim NK
Mol Carcinog; 2013 Nov; 52 Suppl 1():E60-9. PubMed ID: 23169005
[TBL] [Abstract][Full Text] [Related]
15. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer.
Rydén L; Linderholm B; Nielsen NH; Emdin S; Jönsson PE; Landberg G
Breast Cancer Res Treat; 2003 Dec; 82(3):147-54. PubMed ID: 14703061
[TBL] [Abstract][Full Text] [Related]
16. Ginkgo biloba exocarp extracts inhibits angiogenesis and its effects on Wnt/β-catenin-VEGF signaling pathway in Lewis lung cancer.
Han D; Cao C; Su Y; Wang J; Sun J; Chen H; Xu A
J Ethnopharmacol; 2016 Nov; 192():406-412. PubMed ID: 27649680
[TBL] [Abstract][Full Text] [Related]
17. Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma.
Brito AB; Lourenço GJ; Oliveira GB; De Souza CA; Vassallo J; Lima CS
Ann Hematol; 2014 Aug; 93(8):1363-9. PubMed ID: 24687381
[TBL] [Abstract][Full Text] [Related]
18. [Expression of vascular endothelial growth factor and its receptor Flk-1/KDR in benign and malignant breast neoplasms].
Li YJ; Wen G; Wang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan; 29(1):70-1, 74. PubMed ID: 19218116
[TBL] [Abstract][Full Text] [Related]
19. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis.
Knod L; Donovan EC; Chernoguz A; Crawford KM; Dusing MR; Frischer JS
J Surg Res; 2013 Sep; 184(1):101-7. PubMed ID: 23688787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
